姓名:陈策实
学历:博士
专家类别:研究员
邮箱:chenc@kmmu.edu.cn
通讯地址:云南省昆明市呈贡区雨花街道春融西路1168号
邮编:650500
简历
1990.9-1994.7 理学学士,南开大学生命科学院微生物系。
1994.9-1999.6 理学博士,中国科学院上海生物工程研究中心和药物研究所。
1999.6-2002.4 博士后,美国弗吉尼亚(Virginia)大学病理系。
2002.4-2004.6 博士后,美国Emory 大学Winship 癌症研究所。
2004.7-2005.12 讲师,美国Emory 大学Winship 癌症研究所。
2006.1-2009.10 助理教授(Tenure Track),美国阿尔巴尼医学院细胞生物学癌症研究中心。
2009.11-2010.10副教授(Tenure Track),美国阿尔巴尼医学院细胞生物学和癌症研究中心
2010.10-2022.8 研究员,中国科学院昆明动物研究所
2022.9-今 研究员,澳洲5·(中国)集团有限公司,生物医学工程研究院
2023年5月-至今 云南省肿瘤医院副院长
研究方向
主要围绕乳腺癌发病机理进行深入的系统研究,对肿瘤遗传、蛋白质翻译后修饰、转录因子、细胞周期与凋亡、细胞迁移和癌症转移、信号传导、代谢、免疫、干细胞等方向感兴趣,在分子、细胞、模式动物和人等多个层次进行重要基因的功能及其机制研究,建立这些疾病的动物模型用于肿瘤预防与药物筛选。同时与多家医院展开合作,为预防和治疗人类癌症提供诊断/预后的分子标志物以及治疗靶标。目前分为五个方向:
1.蛋白质泛素化修饰与肿瘤
蛋白质泛素化介导的降解可以调节细胞周期,基因转录,DNA修复,迁移,以及凋亡等细胞过程。蛋白质泛素化需要三个酶相继催化完成,负责最后关键一步反应的酶叫做E3泛素连接酶,逆转泛素化修饰的酶叫去泛素化酶(DUB)。我们发现很多E3和DUB,如WWP1, Fbw7, HECTD3, RNF126, BCA2, BAP1,STAMBPL1等在乳腺癌中发生遗传和表达畸变。寻找、鉴定新的肿瘤相关的E3泛素连接酶和去泛素化酶,研究它们作用的分子机制,建立转基因动物模型,并开发它们在临床诊断和治疗的应用是我们主要的一个研究方向。
2.KLF5转录因子与乳腺癌干细胞
KLF5在基底型乳腺癌细胞中高表达。阳性KLF5的表达预示着病人生存时间短。我们多年的功能研究显示KLF5能紧密控制FGF-BP、mPGES1、TNFAIP2和Slug癌基因表达,然后促进细胞周期、生存和肿瘤生长和转移。KLF5的降解主要受到Fbw7和WWP1的控制。Hippo信号通路的YAP和TAZ共转录因子可以增加KLF5的稳定性和活性,从而促进乳腺癌细胞增殖和生存。KLF5的转录受到孕激素信号刺激后上调表达。我们发现乳腺特异性的KLF5 基因敲除小鼠乳腺发育延迟。最近我们发现YB1是KLF5重要的上游正调控因子,PRMT5可以催化KLF5蛋白发生甲基化而稳定,HDAC1促进KLF5去乙酰化而稳定。我们将进一步研究KLF5在乳腺癌中的角色、下游调节基因、相互作用蛋白以及上游调节因子,以期能找到早期诊断预后标志物以及控制这条途径的药物。
3.表观遗传
非编码RNA在人类基因组占比非常高,我们发现miRNA217和miR153在抑制KLF5表达方面发挥重要作用,KLF5诱导的多条lncRNA如IGFL2-AS1, KPRT4, UCA1等介导了KLF5的促癌功能。此外发现NSUN2介导的RNA的m5C修饰以及m5C的读码器YB1促进基底型乳腺癌。IKKa催化的组蛋白H3磷酸化在炎症介导的粘附分子表达和癌症转移中扮演关键角色。计划围绕circRNA的编码功能以及RNA的修饰展开研究,以期能找到早期诊断预后标志物和抗癌药物靶标。
4.肿瘤免疫
肿瘤免疫治疗是近十多年来的一个热门研究方向,为癌症的治疗带来了革命性变化,我们发现KLF5通过促进前列腺素产生导致免疫抑制微环境,HECTD3也通过调节免疫微环境中的巨噬细胞发挥重要作用。拟从肿瘤疫苗,CART新技术,多糖调节免疫系统抗癌等方面展开探索性研究。
5.抗癌药物研发
针对抗癌药物靶点或细胞建立高通量筛选模型,对天然产物和小分子化合物库进行筛选,发现中药痛舒胶囊通过抑制ERa抑制乳腺细胞增殖,升麻提取物KHF16通过抑制NFkB信号通路抑制三阴性乳腺癌,避孕药米非司酮以及衍生物、二甲双胍、光辉霉素、超级增强子抑制剂JQ1/870和THZ1,PRMT5抑制剂PJ68等通过抑制KLF5抑制三阴性乳腺癌干细胞。我们还对具有抗癌作用的先导化合物进行结构改造,优化生物活性,深入进行药理药效学研究,同时对外提供抗癌药物评价和药理研究服务。目前的课题聚焦在PROTAC化合物以及新型天然产物化合物的研发。
承担科研项目
1) 国家自然科学基金重点项目:E3泛素连接酶RNF126通过调节DNA损伤修复促进乳腺癌,81830087,2019年01月至2023年12月,直接费用297万元
2) 国家自然科学基金委-云南省联合重点项目“KLF5通过相变和甲基化识别调控乳腺发育和基底型乳腺癌发生进展的研究”U2102203,2022年01月至2025年12月,直接费用233万元
3) 国家重点研发计划“干细胞及转化研究”重点专项: “上皮间质相互转换在乳腺(癌)干细胞中的功能、分子机制和应用研究”,首席科学家,2020YFA0112300,2020.10-2025.1,直接费用2889万元
4) 云南省科技厅基础研究重点项目:KLF5/IGFL2-AS1/IGFL1轴线调控乳腺癌干细胞的功能和机制研究,202101AS070050,2021-2024,50万元
5)云南省重大科技专项-生物医药专项,乳腺癌类器官库及靶向示踪诊疗技术平台建设和运用,首席科学家,202302AA310046, 2023.6-2026.5,2270万元
6)云南省基础研究重大项目, 首席孙汉董院士,202201BC070002,100万元,参与
专家类别:
研究员,百人计划,国家杰青,万人计划领军人才,云岭学者
获奖及荣誉:
2021年 重庆市科技进步奖一等奖(排名第2)
2018年 云岭学者
2018年 中组部万人计划领军人才
2016年 科技部中青年科技创新领军人才
2015年云南省科技进步奖一等奖(排名第5)
2013年 国家自然科学基金委杰出青年基金
2011年 中国科学院百人计划A类择优(海外杰出科学家)
2010年 云南省高端科技人才
2008年 美国癌症协会研究学者奖
研究成果(论文、专利、专著等)
近5年通讯作者研究论文:
2023年
1) A human-specific insertion promotes cell proliferation and migration by enhancing TBC1D8B expression,Science China-Life Science,2023,in press
2) Zhenbin Wang, Lei Zhang, Bing Li, Jiagui Song, Miao Yu, Jing Zhang, Ceshi Chen*, Jun Zhan*, Hongquan Zhang*, Kindlin-2 in myoepithelium controls luminal progenitor commitment to alveoli in mouse mammary gland, Cell Death & Disease volume 14, article number: 675 (2023)
3) Ting Qiu#, Lei Hou#, Lina Zhao#, Xinye Wang, Zhongmei Zhou, Chuanyu Yang, Huifeng Zhang, Dewei Jiang*, Baowei Jiao*, Ceshi Chen*,SGCE promotes breast cancer stemness by promoting the transcription of FGF- BP1 by Sp1, J Bio Chem,2023, 299(11):105351
4) Huan Fang#,Wenlong Ren#,Qiuxia Cui#,Huichun Liang,Chuanyu Yang, Wenjing Liu,Xinye Wang,Xue Liu,Yujie Shi*,Jing Feng*,Ceshi Chen*,Integrin β4 promotes DNA damage drug resistance in triple-negative breast cancer via the TNFAIP2/IQGAP1/Rac1 axis,Elife, 2023 Oct 3:12:RP88483. doi: 10.7554/eLife.88483.
5)Jia He#, Luzhen Wang#, DaZhao Mi#, Tian Guan#, Wenjing Liu, Peng He, Haijun Gu, Yuzhan Li, Yangrui Peng, Ai-Qun Jia, Ceshi Chen*, Yihua Chen*,Discovery of Pyrimidinediamine Derivatives as Potent Methuosis Inducers for the Treatment of Triple-Negative Breast Cancer,J Med Chem,2023 Jun 8;66(11):7421-7437
6) Qiuxia Cui#, Jian Sun#, Huiping Yuan#, Juanjuan Li, Chuanyu Yang, Guangshi Du, Chengang Zhou, Pu Qiu, Jidong Gao, Yuanqi Zhang*, Dewei Jiang*, Ceshi Chen*, DNA damage chemotherapeutic drugs suppress basal like breast cancer growth through downregulating the transcription of FOXO1-KLF5 axis, Gene&Diseases, 2023, May 2;11(1):91-94.
7) Ping Zhao#, Jian Sun#, Xinwei Huang#, Xiangwu Zhang, Xin Liu, Rong Liu, Guangshi Du, Wenqiang Gan, Chuanyu Yang, Yiyin Tang*, Ceshi Chen*, Dewei Jiang*, Targeting the KLF5-EphA2 axis can restrain cancer stemness and overcome chemoresistance in basal-like breast cancer, Int. J. Biol. Sci. 2023; Mar 21;19(6):1861-1874.
8) Qi Wu#, Zhou Liu#, Zhijie Gao#, Yao Luo#, Fubing Li, ChuanYu Yang, Tiantian Wang, Xiangyu Meng, Haijun Chen, Juanjuan Li, Yanjie Kong*, Chao Dong*, Si Sun*, Ceshi Chen*,KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8+ T-cell-dependent antitumor immunity,Theranostics,2023; 13(4): 1381-1400.
9) Luzhen Wang#, Dazhao Mi# , Jinhui Hu#, Wenjing Liu, Yi Zhang, Chunyan Wang *, Yihua Chen*, Ceshi Chen *,A novel methuosis inducer DZ-514 possesses antitumor activity via activation of ROS-MKK4-p38 axis in triple negative breast cancer,Cancer Letters,555 (2023) 216049.
10) Li Zeng#, Hongyan Zhang#, Chuanyu Yang, Zhuo Cheng ,Qiuyun Jiang, Yao Luo, Yi Li, Fubing Li*, Ceshi Chen* , Generation of a tree shrew breast cancer model using lentivirus expressing PIK3CA-H1047R, Zoological Res, 2023, 44(1): 94?97
11) Wenjing Liu, Min Zheng, Rou Zhang, Qiuyun Jiang, Guangshi Du, Yingying Wu, Chuanyu Yang, Fubing Li, Wei Li, Luzhen Wang, Jiao Wu, Lei Shi, Wenhui Li, Kai Zhang, Zhongmei Zhou, Rong Liu, Yingzheng Gao, Xinwei Huang, Songqing Fan, Xu Zhi*, Dewei Jiang*, Ceshi Chen*, RNF126-Mediated MRE11 Ubiquitination Activates the DNA Damage Response and Confers Resistance of Triple-Negative Breast Cancer to Radiotherapy, Adv Sci, 2023 Vol. 10 Issue 5 Pages e2203884.
2022年
1) Fubing Li#, Huichun Liang#, Hua You, Ji Xiao, Houjun Xia, Xi Chen, Maobo Huang, Zhuo Cheng, Chuanyu Yang, Wenjing Liu, Hailin Zhang, Li Zeng, Yingying Wu, Fei Ge, Zhen Li, Wenhui Zhou, Yi Wen, Zhongmei Zhou, Rong Liu, Dewei Jiang, Ni Xie, Bin Liang, Zhenzhen Liu*, Yanjie Kong*, Ceshi Chen*,HECTD3 promotes tumor metastasis by ubiquitinating IKKa to upregulate expression of adhesion molecules in vascular endothelial cells,Signal Transduction and Targeted Therapy,(2022) 7:264
2) Guangshi Du#, Jian Sun#, Zhen Li#, Qian Zhang, Wenjing Liu, Chuanyu Yang, Ping Zhao, Xinye Wang, Qiyan Yin, Yao Luo, Jinhuan Song, Yi Wen, Haixia Wang, Chuan-Huizi Chen, Guosheng Hu, Zhongmei Zhou, Xiaoyun Mao, Wen Liu, Zhenzhen Liu*, Dewei Jiang*, Ceshi Chen*,A feedforward circuit between KLF5 and lncRNA KPRT4 contributes to basal-like breast cancer,Cancer Letters,Volume 534,2022,215618
3) Yanjie Kong#, Wenlong Ren#, Huan Fang#, Naseer Ali Shah#, Yujie Shi, Dingyun You, Chengang Zhou, Dewei Jiang, Chuanyu Yang, Huichun Liang, Wenjin Liu, Luzhen Wang, Wenqiang Gan, Xing Wan, Fubing Li*, Zhen Li*, Ceshi Chen*, and Ni Xie* , Histone Deacetylase Inhibitors (HDACi) Promote KLF5 Ubiquitination and Degradation in Basal-like Breast Cancer,Int J Biol. Sci., 2022; 18(5): 2104–2115.
4) Rong Liu#*, Guangxi Yang#, Min Bao#, Zhongmei Zhou, Xiaoyun Mao,Wenjing Liu, Xiaoyan Jiang, Di Zhu, Xinle Ren, Jian Huang*, Ceshi Chen*, STAMBPL1 promotes breast cancer cell resistance to cisplatinpartially by stabilizing MKP-1 expression,Oncogene, 2022;41, 2265–2274
5) Dewei Jiang#, Ting Qiu#, Junjiang Peng#, Siyuan Li#, Tala, Wenlong Ren, Chuanyu Yang, Yi Wen,Chuan-HuiziChen, Jian Sun, Yingying Wu, Rong Liu, Jun Zhou, Kongming Wu, Wen Liu, Xiaoyun Mao*, Zhongmei Zhou*, Ceshi Chen*,YB-1 is a positive regulator of KLF5 transcription factor in basal-like breast cancer,Cell Death and Differentiation, 2022
2021年
1) Jian Sun#, Wenjing Liu #, Yongbo Guo, Hailin Zhang, Dewei Jiang, Ying Luo, Rong Liu, Ceshi Chen*, Characterization of tree shrew telomeres and telomerase,Journal of Genetics and Genomics, 2021,48,631-639
2) Haixia Wang#, Yujie Shi#, Chuan-Huizi Chen, Yi Wen, Zhongmei Zhou, Chuanyu Yang,Jian Sun, Guangshi Du, Jiao Wu, Xiaoyun Mao, Rong Liu, Ceshi Chen, KLF5-induced lncRNA IGFL2-AS1 promotes basal-like breast cancer cellgrowth and survival by upregulating the expression of IGFL1,Cancer Letters, 2021,515: 49-62
3) Xinye Wang#, Ting Qiu#, Yingying Wu, Chuanyu Yang, Yi Li, Guang-Shi Du, Yaohui He, Wen Liu, Rong Liu, Chuan-Huizi Chen, Yu-Jie Shi, Jingxuan Pan, Jia Zhou, Dewei Jiang*, and Ceshi Chen*, Arginine methyltransferase PRMT5 methylates and stabilizes KLF5 via decreasing its phosphorylation and ubiquitination to promote basal like breast cancer,Cell Death and Differentiation, 2021;28(10):2931-2945.
4) Jiao Wu#, Sai-Ching Jim Yeung#, Sicheng Liu#, AihamQdaisat, Dewei Jiang, Wenli Liu, Zhuo Cheng, Wenjing Liu, Haixia Wang, Lu Li, Zhongmei Zhou, Rong Liu, Chuanyu Yang, Ceshi Chen*, Runxiang Yang*, Cyst(e)ine in Nutrition Formulation Promotes Colon Cancer Growth and Chemoresistance by Activating mTORC1 and Scavenging ROS,Signal Transduction and Targeted Therapy,2021,6:188
5) Maobo Huang#, Yuanfei Zhou#, DongzhuDuan#, Chuanyu Yang, Zhongmei Zhou, Fubing Li, Yanjie Kong, Yi-Ching Hsieh, Ruihan Zhang, Wenping Ding, Weilie Xiao, PemaTenzin Puno*, Ceshi Chen*, Targeting ubiquitin conjugating enzyme UbcH5b by a triterpenoid PC3-15 from Schisandra plants sensitizes triple-negative breast cancer cells to lapatinib,Cancer Letters, 2021, 504,125-36
6) Benfu Zhong#, Dewei Jiang#, Yang Hong, Lifang Li, Li Qiu, Ronghui Yang, XiaohanJin, Yawen Song, Ceshi Chen*, Binghui Li*, Glucose-6-phosphate dehydrogenase neutralizes stresses by supporting reductive glutamine metabolism and AMPK activation,Signal Transduction and Targeted Therapy,2021,6(46)
7) Xiaoyan Jiang#, Xu Zhi#, Peixia Zhang, Zhongmei Zhou, Jinxiang Ye, Yu Gao, Xinye Wang, Chuanyu Yang, Haijun Chen*, Rong Liu* and Ceshi Chen*, Isochromanoindolenines suppress triple-negative breast cancer cell proliferation partially via inhibiting Akt activation,Int J Biol. Sci., 2021; 17(4):986-994
2020年
1) Danping Wang#, ZhiNie#, Xiaoyan Jiang, Jinxiang Ye, Zhimin Wei, Dating Cheng, Chenyang Wang, Yingying Wu, Rong Liu*, Haijun Chen*, Ceshi Chen*, Chunyan Wang*, Pyrrolo[3,4-b]-quinolin-9-amine compound FZU-0038-056 suppresses triple-negative breast cancer partially through inhibiting the expression of Bcl-2 ,Aging, 2020, May 23;12.
2) Lina Zhao#, Ting Qiu#, Dewei Jiang#, Haibo Xu, Li Zou, Qin Yang, Ceshi Chen *, Baowei Jiao*, SGCE promotes breast cancer stem cells by stabilizing EGFR,Advanced Science, 2020, https://doi.org/10.1002/advs.201903700
3) Wenjing Liu#, Xiaoqing Lu#, Peiguo Shi#, Guangxi Yang, Zhongmei Zhou, Wei Li, Xiaoyun Mao*, Dewei Jiang* & Ceshi Chen*, TNF-a increases breast cancer stem-like cells through upregulating TAZ expression via the non-canonical NF-kB pathway,Scientific Reports, 10, 1804 (2020). https://doi.org/10.1038/s41598-020-58642-y
4) Rong Liu#, Haijun Chen#, Ping Zhao, Chuan-Huizi Chen, Huichun Liang, Chuanyu Yang, Zhongmei Zhou, Xu Zhi, Suling Liu, Ceshi Chen*,Mifepristone Derivative FZU-00,003 Suppresses Triple-negative Breast Cancer Cell Growth partially via miR-153-KLF5 axis,Int J Biol. Sci., 2020; 16(4):611-619
5) Rui-DanBao, Xue-QingSong, Yan-jieKong, Fang-FangLi, Wen-HuiLiao, JieZhou, Ji-hongZhang, Qi-HuaZhao, Jing-YuanXu, Ce-shiChen*, Ming-JinXie*, A new Schiff base copper(II) complex induces cancer cell growth inhibition and apoptosis by multiple mechanisms, Journal of Inorganic Biochemistry, 2020, Jul;208:111103.
2019年
1) Yingying Wu, QunyingQin ,Fubing Li , Chuanyu Yang , Zhen Li , Zhongmei Zhou , Hailin Zhang , Yunxi Li , Xinye Wang , Rong Liu , Qian Tao , Wenlin Chen*, Ceshi Chen*, USP3 promotes breast cancer cell proliferation by deubiquitinating KLF5,J. Biol. Chem.2019, 294(47),17837-47
2) LingliHe , Liang Yuan , Yang Sun , Pingyang Wang , Hailin Zhang , Xue Feng , Zuoyun Wang , Wenxiang Zhang , Chuanyu Yang , Yi Arial Zeng , Yun Zhao , Ceshi Chen*, Lei Zhang*, Glucocorticoid receptor signaling promotes breast cancer progression by activating TEAD4,CancerRes, 2019, 79(17):4399-4411.
3) Yanjie Kong*, Zehua Wang*, Maobo Huang, Zhongmei Zhou, Yi Li, Huilai Miao, Xing Wan, Jian Huang, Xiaoyun Mao#, Ceshi Chen#, CUL7 promotes cancer cell survival through promoting Caspase-8 ubiquitination,Int J Cancer,2019 ,145(5):1371-1381
4) Wenhui Zhou#, Huan Fang#, Qiuju Wu#, Xinye Wang, Rong Liu, Fubin Li, Ji Xiao, Lin Yuan, Zhongmei Zhou, Junying Ma, Lulu Wang, Weiwei Zhao, Hua You, Jianhua Ju, Jing Feng*, Ceshi Chen*, Ilamycin E, a natural product of marine actinomycete, inhibits triple-negative breast cancer partially through ER stress-CHOP-Bcl-2,Int J Biol. Sci., 2019; 15(8): 1723-1732
5) Chuan-Huizi Chen, Nong Yang, Yongchang Zhang, Jiancheng Ding, Wenjuan Zhang, Rong Liu, Wen Liu*, Ceshi Chen*, Inhibition of super enhancer downregulates the expression of KLF5 in basal-like breast cancers,Int J Biol. Sci., 2019; 15(8): 1733-1742.
近5年综述论文:
1) Qiyan Yin#, Min Zheng#, Qianmei Luo, Dewei Jiang, Huifeng Zhang*, Ceshi Chen*, YB-1 as an oncoprotein: functions, regulation, post-translational modifications, and targeted therapy,Cells, 2022
2) Xuerong Wang#, Chao Wang#, Jiaheng Guan#, Baoan Chen,Lin Xu*, Ceshi Chen*,Progresses of breast cancer basic research in China,Int J Biol. Sci.,2021; 17(8): 2069-2079.
3) Yao Luo, Ceshi Chen, The Roles and Regulation of the KLF5 Transcription Factor in Cancers,Cancer Science, 2021,112(6): 2097–2117.
4) Ping Zhao#, Dewei Jiang#, Yunchao Huang*, Ceshi Chen*, EphA2: a promising therapeutic target in breast cancer,Journal of Genetics and Genomics, 2021,48(4):261-267.
5) Chao Dong#, Jiao Wu#, Yin Chen, JianyunNie* and Ceshi Chen*, Activation of PI3K/AKT/mTOR pathway causes drug resistance in breast cancer,Front. Pharmacol. 2021, 12:628690. doi: 10.3389/fphar.2021.628690
6) Zhen Li, Wei Zou, Ji Zhang, Yunjiao Zhang, Qi Xu, Siyuan Li, Ceshi Chen*, Mechanisms of CDK4/6 inhibitor resistance in luminal breast cancer,Front. Pharmacol. 11:580251. doi: 10.3389/fphar.2020.580251
7) Li Zeng, Wei Li, Ceshi Chen*, Breast cancer animal models and applications,Zoological Research, 2020, Sep 18;41(5):477-494. doi: 10.24272/j.issn.2095-8137.2020.095.
8) RouZhang, WenjinLiu, JianSun, YanjieKong, Ceshi Chen*, Roles of RNF126 and BCA2 E3 ubiquitin ligases in DNA damage repair signaling and targeted cancer therapy, Pharmacological Research, 6 March 2020, https://doi.org/10.1016/j.phrs.2020.104748
9) Qiuyun Jiang, Fubing Li, Zhuo Cheng, Yanjie Kong, Ceshi Chen*, The role of E3 ubiquitin ligase HECTD3 in cancer and beyond,Cellular and Molecular Life Sciences, 2019, Oct 21. doi: 10.1007/s00018-019-03339-3.
10) Lin Jia, Yundong Shi, Yi Wen, Wei Li, Jing Feng, Ceshi Chen*, The roles of TNFAIP2 in cancers and infectious diseases,J Cell Mol Med.2018;22:5188–5195.
近5年非SCI论文以及专著
1) 郑敏,李薇,陈策实,精准肿瘤学,第43章细胞培养和动物模型的建立,科学出版社,p 329-355,2022年10月第一版。
2) 陈策实,青年医师如何做好科研,中华乳腺病杂志(电子版),2022,16(1):28
3) Yingying Wu, Qiuting Zhang, and Ceshi Chen,Heterogeneity and Subtyping of Triple-Negative Breast Cancer (Book Chapter), Triple-Negative Breast Cancer, World Scientific, 2021, ISBN, 978-3277-75-5, 21-40.
4) 李富兵,陈策实,泛素家族介导的蛋白质降解和细胞自噬,第十六章泛素化调节细胞死亡,科学出版社,p389-417,2020年6月第一版。
5)侯雷,罗倩梅,李玲睿,陈策实,类器官及其应用,上海科学技术出版社,第九章,乳腺癌类器官,p225-246,2023年11月第一版
专利:
1)一种乳头注射慢病毒建立树鼩乳腺癌模型的方法 专利号:ZL201310133542.1授权日期20150218, 陈策实、夏厚军、何保丽、角建林
2)米非司酮衍生物及其用途 专利号:CN106397527 B授权日期:2019年7月26日, 陈策实、陈海军、刘蓉
3)3 ,4断裂的环阿尔廷型三萜类化合物在制备自噬抑制剂及抗肿瘤药物中的应用,申请号202010405627 .0,申请日2020 .05 .14,陈策实 普诺·白玛丹增 孙汉董 黄茂波 周元飞
4)一类诱导肿瘤细胞发生Methuosis死亡的三芳香杂环哌嗪类化合物及其应用,陈益华,陈策实,何佳等,2023年,申请中